替西帕肽获得美国食品和药物管理局批准用于治疗阻塞性睡眠呼吸暂停:对口腔卫生保健提供者的影响

IF 3.1 2区 医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE
Mohamed G Hassan, Dina G Hassan, Gamaleldin A Hassan
{"title":"替西帕肽获得美国食品和药物管理局批准用于治疗阻塞性睡眠呼吸暂停:对口腔卫生保健提供者的影响","authors":"Mohamed G Hassan, Dina G Hassan, Gamaleldin A Hassan","doi":"10.1016/j.adaj.2025.05.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory complications, reducing overall health and quality of life. The authors aimed to provide oral health care providers with an update on the US Food and Drug Administration-approved medication tirzepatide (Zepbound; Lilly) and its implications for multidisciplinary OSA management and oral health care-related services.</p><p><strong>Types of studies reviewed: </strong>A comprehensive MEDLINE search was conducted, and original research articles and systematic reviews related to OSA and tirzepatide were reviewed.</p><p><strong>Results: </strong>A multidisciplinary approach involving lifestyle modifications, pharmaceutical interventions, oral appliance therapy, and surgical options tailored to patient-specific needs is required for effective management of OSA. In 2024, the US Food and Drug Administration approved tirzepatide for managing obesity in adults with OSA. By means of promoting weight loss, tirzepatide has been found to reduce breathing interruptions and enhance sleep quality. Although dental care providers do not prescribe tirzepatide, they play a critical role in early identification and referral of patients at risk of experiencing OSA through clinical screening. They recognize craniofacial features associated with airway obstruction, provide oral appliance therapy, and collaborate closely with health care providers.</p><p><strong>Practical implications: </strong>Tirzepatide offers a novel approach to managing OSA by means of targeting metabolic and inflammatory factors that contribute to this condition. It has the potential to affect oral health, including the management of periodontal disease, dental implant procedures, and orthodontic interventions. Dental care providers should consider patient-centered needs and the interrelationship between systemic health and oral health.</p>","PeriodicalId":17197,"journal":{"name":"Journal of the American Dental Association","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.\",\"authors\":\"Mohamed G Hassan, Dina G Hassan, Gamaleldin A Hassan\",\"doi\":\"10.1016/j.adaj.2025.05.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory complications, reducing overall health and quality of life. The authors aimed to provide oral health care providers with an update on the US Food and Drug Administration-approved medication tirzepatide (Zepbound; Lilly) and its implications for multidisciplinary OSA management and oral health care-related services.</p><p><strong>Types of studies reviewed: </strong>A comprehensive MEDLINE search was conducted, and original research articles and systematic reviews related to OSA and tirzepatide were reviewed.</p><p><strong>Results: </strong>A multidisciplinary approach involving lifestyle modifications, pharmaceutical interventions, oral appliance therapy, and surgical options tailored to patient-specific needs is required for effective management of OSA. In 2024, the US Food and Drug Administration approved tirzepatide for managing obesity in adults with OSA. By means of promoting weight loss, tirzepatide has been found to reduce breathing interruptions and enhance sleep quality. Although dental care providers do not prescribe tirzepatide, they play a critical role in early identification and referral of patients at risk of experiencing OSA through clinical screening. They recognize craniofacial features associated with airway obstruction, provide oral appliance therapy, and collaborate closely with health care providers.</p><p><strong>Practical implications: </strong>Tirzepatide offers a novel approach to managing OSA by means of targeting metabolic and inflammatory factors that contribute to this condition. It has the potential to affect oral health, including the management of periodontal disease, dental implant procedures, and orthodontic interventions. Dental care providers should consider patient-centered needs and the interrelationship between systemic health and oral health.</p>\",\"PeriodicalId\":17197,\"journal\":{\"name\":\"Journal of the American Dental Association\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Dental Association\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.adaj.2025.05.007\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Dental Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.adaj.2025.05.007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0

摘要

背景:阻塞性睡眠呼吸暂停(OSA)是一种常见的疾病,其特征是睡眠期间气道反复塌陷,导致呼吸中断。阻塞性睡眠呼吸暂停会增加患高血压、心脏病、中风和呼吸系统并发症的风险,降低整体健康水平和生活质量。作者旨在为口腔卫生保健提供者提供美国食品和药物管理局批准的药物替西肽(Zepbound;及其对多学科OSA管理和口腔保健相关服务的影响。回顾的研究类型:进行了全面的MEDLINE检索,回顾了与OSA和替西帕肽相关的原始研究文章和系统综述。结果:OSA的有效治疗需要多学科的方法,包括改变生活方式、药物干预、口腔矫治器治疗和针对患者具体需求的手术选择。2024年,美国食品和药物管理局批准替西帕肽用于治疗阻塞性睡眠呼吸暂停症成人的肥胖。通过促进减肥,替西帕肽已被发现减少呼吸中断和提高睡眠质量。虽然牙科保健提供者不开替西帕肽,但通过临床筛查,替西帕肽在早期识别和转诊有OSA风险的患者方面发挥着关键作用。他们识别与气道阻塞相关的颅面特征,提供口腔矫治器治疗,并与卫生保健提供者密切合作。实际意义:替西帕肽通过靶向导致OSA的代谢和炎症因子,提供了一种治疗OSA的新方法。它有可能影响口腔健康,包括牙周病的管理、种植牙程序和正畸干预。牙科保健提供者应考虑以病人为中心的需要以及全身健康和口腔健康之间的相互关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.

Background: Obstructive sleep apnea (OSA) is a common condition characterized by repeated airway collapse during sleep, leading to breathing interruptions. OSA increases the risk of developing hypertension, heart disease, stroke, and respiratory complications, reducing overall health and quality of life. The authors aimed to provide oral health care providers with an update on the US Food and Drug Administration-approved medication tirzepatide (Zepbound; Lilly) and its implications for multidisciplinary OSA management and oral health care-related services.

Types of studies reviewed: A comprehensive MEDLINE search was conducted, and original research articles and systematic reviews related to OSA and tirzepatide were reviewed.

Results: A multidisciplinary approach involving lifestyle modifications, pharmaceutical interventions, oral appliance therapy, and surgical options tailored to patient-specific needs is required for effective management of OSA. In 2024, the US Food and Drug Administration approved tirzepatide for managing obesity in adults with OSA. By means of promoting weight loss, tirzepatide has been found to reduce breathing interruptions and enhance sleep quality. Although dental care providers do not prescribe tirzepatide, they play a critical role in early identification and referral of patients at risk of experiencing OSA through clinical screening. They recognize craniofacial features associated with airway obstruction, provide oral appliance therapy, and collaborate closely with health care providers.

Practical implications: Tirzepatide offers a novel approach to managing OSA by means of targeting metabolic and inflammatory factors that contribute to this condition. It has the potential to affect oral health, including the management of periodontal disease, dental implant procedures, and orthodontic interventions. Dental care providers should consider patient-centered needs and the interrelationship between systemic health and oral health.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of the American Dental Association
Journal of the American Dental Association 医学-牙科与口腔外科
CiteScore
5.30
自引率
10.30%
发文量
221
审稿时长
34 days
期刊介绍: There is not a single source or solution to help dentists in their quest for lifelong learning, improving dental practice, and dental well-being. JADA+, along with The Journal of the American Dental Association, is striving to do just that, bringing together practical content covering dentistry topics and procedures to help dentists—both general dentists and specialists—provide better patient care and improve oral health and well-being. This is a work in progress; as we add more content, covering more topics of interest, it will continue to expand, becoming an ever-more essential source of oral health knowledge.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信